New: OMG Experience Expands European Air Freight Routes — New direct services to Zurich, Lisbon, and Warsaw Read more →
How Thailand B.E. 2568 controlled-herb rules reshape medical cannabis export: DTAM oversight, export licensing intent, permit documentation, and what EU importers expect when sourcing from Thai operators.
Thailand’s evolution toward a controlled-herb, medical-forward framework—often discussed in the context of B.E. 2568 policy direction—fundamentally changes how operators should think about export. Where general commercial narratives once dominated public discussion, the durable pathway for international movement is now tightly coupled to medical purpose, research justification, and traceable batches that can survive questions from both Thai authorities and destination regulators. This guide is written for exporters, quality leaders, and logistics partners who need a plain-language map of what “compliance-ready” documentation looks like before the first pallet leaves the country.
Scope note: This article is educational context for teams building internal playbooks. It is not legal advice for a specific licence, permit line, or member state filing. Always confirm classifications, permit wording, and reporting duties with qualified Thai counsel and your EU importer’s regulatory affairs function.
If those four functions never meet in one room before the first export, you will pay for the gap in rework, re-labelling, or stranded cargo.
Search traffic around Thailand medical cannabis export, controlled herb licensing, and DTAM oversight usually comes from teams doing pre-shipment risk review: legal, QA, and customs brokers who want to know whether a Thai supplier is describing product as herbal medicine, research material, or something that still carries narcotics-adjacent obligations. The practical answer is that terminology on the permit line must match the dossier story end-to-end. EU partners will not reconcile conflicting descriptions between your certificate of analysis, commercial invoice, and permit during a live customs hold—they will walk away or delay until every document agrees.
Imagine three documents: (A) permit application narrative, (B) commercial invoice product description, (C) COA header/footer product name. If A says “research material,” B says “herbal raw material for pharmacy,” and C says “dried inflorescence, medical cannabis,” you have created three parallel products in the eyes of a conservative reviewer. The fix is boring but non-negotiable: a controlled vocabulary table in your quality agreement annex that lists approved synonyms and forbidden drift—then train sales and logistics to use only approved strings.
Medical or research purpose statements should not be boilerplate. They should tie to a named dosage form category or research protocol class your importer can defend. Vague language (“for medical use in Europe”) is weaker than language aligned to how the destination member state classifies incoming cannabis medicines.
Source and quantity traceability means more than a farm name on a packing list. It implies lot genealogy: which plots, which harvest windows, which drying or trimming steps, which intermediate storage locations, and which QC release authorized the material for export. If your internal ERP cannot print that chain in one PDF index, you are not yet operating at the level EU GMP and GDP partners expect.
Domestic licence scope versus destination end-use is a common failure mode. An exporter may hold a broad domestic authorization while the EU importer only holds authorization for specific presentations (e.g., dried flower for pharmacy dispensing vs. extract for manufacturing). Align those scopes before you invest in stability studies or repeat harvests.
Treat export permitting as a living program. Each shipment should be defensible as a medical-grade movement with files that customs, health authorities, and your customer’s QP can read without asking you to “fill gaps” by email. That includes version-controlled SOPs, deviation logs for any reprocessing, and photographic or sensor evidence where temperature or security matters.
European procurement teams often run red-team reviews on Asian origin files. They search for date alignment (harvest date vs. test date vs. packaging date), unit consistency (kg vs. lb vs. plant count), and signatory authority on certificates. Long-form narrative in your quality manual or site master file reduces friction because it preempts the same questions every new auditor asks.
Brokers are not magicians—they amplify the quality of your master data. Give them one canonical product data sheet per SKU with: botanical name, part of plant, physical form, intended use category (as approved for discussion with counsel), storage condition statement, and emergency contact tree. Update the sheet with version numbers; brokers forwarding v3 while you ship v4 labels is a classic failure mode.
For batch IDs and reporting cadence, read THC Thresholds, Narcotics Exceptions & Seed-to-Sale Traceability. For farm evidence, read Thai GACP: Farm-Level Quality as the EU-Readiness Baseline. For post-harvest regulatory character, read EU-GMP & Annex 7. None of these replaces permit counsel—they align operations to permit reality.
Often yes, or at minimum different supporting narratives attached to the same permit family. Research movements typically require protocol identifiers, institutional approvals, and importer research licences mirrored on the EU side. Treat research and commercial as two document stacks, not one template with swapped letterhead.
Expect reporting and inspection readiness around quantities produced, quantities in storage, and outbound destinations. Digital systems that log every transfer reduce last-minute spreadsheet reconstruction when an authority requests a 30-day movement history.
At minimum: botanical identity, batch ID, net quantity, form (flower, trim, extract if applicable), intended use category, and consignee legal entity. Mismatches here are the top reason airport warehouses freeze cargo.
No. THC concentration is one line item in a broader specification. EU partners care about full cannabinoid profile, terpene claims, microbial limits, pesticide panels, and foreign matter—aligned to the product specification you jointly signed.
Before the first permit application draft is submitted. Retrofitting importer-aligned language after permit issuance costs weeks and sometimes requires re-labelling or re-packaging.
When you can show an immutable event log (harvest → test → pack → release) tied to user accounts and timestamps, authorities and partners gain confidence faster than when the same story lives in email threads and shared drives.
Marketing should stay aligned but not overclaim. Use hedged language (“aligned to a medical-only supply chain model”) and link to long-form resources like this page. Let contracts and permits carry the binding statements.
Treat it as a change control: re-run permit narrative, label review, COA footers, and stability rationale if climate zones or dosage form assumptions shift. Silent pivots are how auditors find critical inconsistencies.
Maintain signed training logs, quiz results or skills checklists, and periodic refresher dates. Generic “all staff trained” memos without names and dates fail credible evidence tests.
Only if your licence, customer spec, and risk assessment explicitly allow both presentations and you maintain physical segregation with separate batch IDs. Commingling destroys defensible traceability.
Quality Assurance should own the controlled vocabulary with legal sign-off on regulatory-sensitive phrases. Sales proposes; QA + legal approve; no exceptions on customer-facing PDFs.
Time-to-complete batch index from harvest to export-ready PDF—aim to compress it every quarter. Speed without accuracy is dangerous; accuracy with predictable turnaround wins repeat orders.
